Session Details
[O]Flaviviridae 3
Tue. Nov 3, 2026 3:15 PM - 4:15 PM JST
Tue. Nov 3, 2026 6:15 AM - 7:15 AM UTC
Tue. Nov 3, 2026 6:15 AM - 7:15 AM UTC
Room 3 (3F Room 301)
Chair: Moi Meng Ling (Department of Developmental Medical Sciences, School of International Health, Graduate School of Medicine, The University of Tokyo)
Chang Kweng Lim (Department of Virology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS))
Chang Kweng Lim (Department of Virology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS))
[O2-3-11]A tunable immune-evasion function of Zika virus NS5 governs viral fitness and pathogenesis
Yu Zhang1, Yaqing Zhang1, Yongqi Guo1, *Qiang Ding1 (1. Tsinghua University)
[O2-3-12]Novel dengue virus non-structural protein vaccine that can avoid disease exacerbation caused by existing vaccines
*Kyoko Kohara1, Jyunichiro Takano2, Bouchra Kitab1, Mohammad EH Kayesh1, Asako Takagi3, Fumihiko Yasui3, Mya Myat Ngew Tun4, Ryosuke Suzuki5, Atsushi Yamanaka6, Kouji Ishii5, Yasuhiro Yasutomi2, Kouichi Morita4, Michinori Kohara3 (1. Kagoshima University, 2. Tukuba Primate Medical Research Center, 3. Tokyo Metropolitan Institute of Medical Science, 4. Nagasaki University, 5. NIID, 6. Osaka University)
[O2-3-13]Functional Characterization of DENV1 Full-Length Clones Bearing Insect-Specific Envelope Fusion Loop Mutations
*Irish Coleen Angelo Asin1, Adeline Yeo Syin Lian1, Kazumi Haga1, Meng Ling Moi1 (1. School of International Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku Tokyo 113-0033 Japan)
[O2-3-14]Attenuation and Imunogenity of a Recombinant Kunjin Virus Vaccine Candidate for West Nile Virus
*Hiromi Abe Chayama1, Shigeru Tajima1, Hitomi Kinoshita1, Eri Nakayama1, Syoko Nishiyama1, Satoshi Taniguchi1, Hideki Ebihara1, Chang-Kweng Lim1 (1. Japan Institute for Health Security)
[O2-3-15]Identification of host factors involved in dengue virus replication and development of antisense oligonucleotide-based therapeutics
*Makoto Shimooka1, Harumi Yamaguma2, Natsumi Kameoka2, Itsuki Anzai1, Satoshi Obika3,4,5,6, Yuuya Kasahara2,5, Tokiko Watanabe1,3,4 (1. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka, 2. National Institutes of Biomedical Innovation, Health and Nutrition, 3. Center for Infectious Disease Education and Research, The University of Osaka, 4. Center for Advanced Modalities and DDS, The University of Osaka, 5. Graduate School of Pharmaceutical Sciences, The University of Osaka, 6. Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka)